Succinate salt of O-desmethyl-venlafaxine

Details Succinate salt of O-desmethyl-venlafaxine Succinate salt of O-desmethyl-venlafaxine

2007-11-06

2007-11-06

Zucker, Paul A. (Department: 1621)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C424S464000, C514S554000

Reexamination Certificate

active

11334223

ABSTRACT:
A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.

REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4761501 (1988-08-01), Husbands et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5788986 (1998-08-01), Dodman
patent: 5916923 (1999-06-01), Rudolph et al.
patent: 6310101 (2001-10-01), Rudolph et al.
patent: 6342533 (2002-01-01), Jerussi et al.
patent: 6441048 (2002-08-01), Jerussi et al.
patent: 6444708 (2002-09-01), Rudolph et al.
patent: 6465524 (2002-10-01), Rudolph et al.
patent: 6555586 (2003-04-01), Rudolph et al.
patent: 6673838 (2004-01-01), Hadfield et al.
patent: 6730706 (2004-05-01), Rudolph et al.
patent: 2003/0149112 (2003-08-01), Yardley et al.
patent: 2003/0236309 (2003-12-01), Hadfield et al.
patent: 2004/0106576 (2004-06-01), Jerussi et al.
patent: 2004/0110829 (2004-06-01), Rudolph et al.
patent: 2004/0180952 (2004-09-01), Jerussi et al.
patent: 2004/0181093 (2004-09-01), Kim et al.
patent: 2005/0175698 (2005-08-01), Diorio et al.
patent: 0 112 669 (1984-07-01), None
patent: 0112669 (1984-07-01), None
patent: 0654264 (1995-05-01), None
patent: 2227743 (1990-08-01), None
patent: WO 9400047 (1994-01-01), None
patent: WO 9400114 (1994-01-01), None
patent: WO 00/32555 (2000-06-01), None
patent: WO 00/59851 (2000-10-01), None
patent: WO 00/76955 (2000-12-01), None
Majetich et al., Tetrahedron Letters, 1994, 8727-8730, 35(47).
Taft et al., “Application of a First-Pass Effect Model to Characterize the Pharmacokinetic Disposition of Venlafaxine After Oral Administration to Human Subjects”, Drug Metabolism and Disposition, 25(10): 1215-18, 1997.
Askew et al., “A Simple Screening Procedure for Imipramine-Like Antidepressant Agents”, Life Sciences No. 10, 725-730, 1963.
Castello et al., “Discoloration of Tablets Containing Amines and Lactose”, J. Pharm. Sci., 51(2): 106-08, 1962.
Handbook of Pharmaceutical Excipients, 2nded., Wade and Willer eds., p. 257-9, 1994.
Haskins et al., “DMI, Wy-45,030, Wy-45, 881 and Ciramadol Inhibit Locus Coeruleus Neuronal Activity”, European Journal of Pharmacology, 115: 139-46, 1985.
Howell, “Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals”, Xenobiotical, 24(4): 315-27, 1994.
Klamerus et al., “Introduction of a Composite Parameter to the Pharmacokinetics of venlafaxine and its Active O-Desmethyl Metabolite”, J. Clin. Pharmacol, 32: 716-24, 1992.
Moyer et al., “Subsensitivity of the Beta-Adrenergic Receptor-Linked Adenylate Cyclase System of Rat Pineal Gland Following Repeated Treatment with Desmethylimipramine and Nialamide”, Molecular Pharmacology, 19: 187-93, 1981.
Moyer et al., “in Vivo Antidepressant Profiles of the Novel Bicyclic Compounds Wy-45,030 and Wy-45,881”, Abstracts Society for Neuroscience, p. 261, 1984.
Muth et al., “Biochemical Neurophysiological, and Behavioral Effects of Wy-45,233 and Other Identified Metabolites of the Antidepressant Venlafaxine”, Drug Develop Res., 23: 191-99, 1991.
Muth et al., Antidepressant Biochemical Profile of the Novel Bicyclic Compounds Wy-45,030, and Ethyl Cyclohexanol Derivative, Biochemical Pharmacology, 35(24): 4493-97, 1986.
Pento, “WY:-45030” Drugs of the Future, 13(9): 839-40, 1988.
Physicians Desk Reference, 53rded., P.3293-3302, 1999.
Remingtons: The Practice of the Science and Pharmacy, 19thed., Gennaro, ed., p. 1625, 1995.
Rudaz et al., “Enantioseparation of Venlafaxine and O-Desmethylvenlafaxine by Capillary Electrophoresis with Mixed Cyclodextrines”, Chromatographia, 50(5/6): 369-372, 1999.
Sinclair et al., “The Tolerability of Venlafaxine”, Rev. contemp. Pharmacother, 9: 333-334, 1988.
Steiner et al., “Radioimmunoassay for Cyclic Nucleotides”, the Journal of Biological Chemistry, 247(4): 1106-1113.
von Moltke et al., “Venlafaxine and Metabolites are Very Weak Inhibitors of Human Cytochrome P450-3A Isoforms”, Biol. Psychiatry, 41: 377-80, 1997.
Wang et al., “The Disposition of Venlafaxine Enantiomers in Dogs, Rats, and Humans Receiving Venlafaxine”, Chirality, 4(2): 84-90, 1992.
Wilen et al., Tetrahedron Report Number 38, Strategies in Optical Resolutions, Tetrahedron, 33: 2725-2736; 1977.
Wood et al., “The Rapid Preparation of Synaptosmes, Using a Vertical Rotor”, Journal of Neurochemistry, 37(3): 795-797, 1981.
Yardley et al., “2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity”, J. Med. Chem. 33:2899-2905, 1990.
Office Action for U.S.S.N. 10/720,134 mailed on Jul. 5, 2007 by the USPTO.

Affiliated with

Also associated with

Rating

Succinate salt of O-desmethyl-venlafaxine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Succinate salt of O-desmethyl-venlafaxine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Succinate salt of O-desmethyl-venlafaxine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3859916